Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma. Adding Keytruda (pembrolizumab) to Lenvima (lenvatinib) led to better duration of ...

Among the 27 responding patients, 81% had a duration of response (DOR) of six months or longer, and 37% had a DOR of 12 months or longer. In June 2020, KEYTRUDA was granted its first indication in ...

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...

Dosage for Keytruda may vary based on the condition it’s being used to treat. The typical starting dose is 200 mg every 3 weeks or 400 mg every 6 weeks. Your doctor may adjust your dosage. The active ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...

Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and melanoma ...

Merck & Co.’s Keytruda has added a third bladder cancer use to its label. With an FDA nod Wednesday, Keytruda has become the first PD-1/L1 inhibitor approved to treat patients with superficial but ...

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...